QBECO

Drug Profile

QBECO

Alternative Names: QBECO SSI

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Qu Biologics
  • Class Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Colorectal cancer

Most Recent Events

  • 14 Aug 2017 Qu Biologics receives positive feedback from the US FDA in response to pre-IND meeting package for expansion of inflammatory bowel disease programme to the US
  • 02 Aug 2017 Interim efficacy data from a phase II trial in Ulcerative colitis released by Qu Biologics
  • 19 Apr 2017 Efficacy data from a phase I/IIb trial in Crohn’s disease released by Qu Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top